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AbsTrACT
Purpose acute respiratory failure (arF) is a common 
cause of admission to intensive care units (icUs). 
Mucoactive agents are medications that promote mucus 
clearance and are frequently administered in patients 
with arF, despite a lack of evidence to underpin clinical 
decision making. The aim of this systematic review was 
to determine if the use of mucoactive agents in patients 
with arF improves clinical outcomes.
Methods We searched electronic and grey literature 
(January 2020). Two reviewers independently screened, 
selected, extracted data and quality assessed studies. 
We included trials of adults receiving ventilatory support 
for arF and involving at least one mucoactive agent 
compared with placebo or standard care. Outcomes 
included duration of mechanical ventilation. Meta- 
analysis was undertaken using random- effects modelling 
and certainty of the evidence was assessed using grades 
of recommendation, assessment, Development and 
evaluation.
results Thirteen randomised controlled trials were 
included (1712 patients), investigating four different 
mucoactive agents. Mucoactive agents showed no effect 
on duration of mechanical ventilation (seven trials, 
mean difference (MD) −1.34, 95% ci −2.97 to 0.29, 
i2=82%, very low certainty) or mortality, hospital stay 
and ventilator- free days. There was an effect on reducing 
icU length of stay in the mucoactive agent groups (10 
trials, MD −3.22, 95% ci −5.49 to −0.96, i2=89%, very 
low certainty).
Conclusion Our findings do not support the use of 
mucoactive agents in critically ill patients with arF. 
The existing evidence is of low quality. high- quality 
randomised controlled trials are needed to determine the 
role of specific mucoactive agents in critically ill patients 
with arF.
PrOsPErO registration number crD42018095408.
InTrOduCTIOn
Acute respiratory failure (ARF) is a common cause 
of admission into intensive care units (ICUs) and 
is associated with high acute and late mortality 
rates.1–3 The mainstay of respiratory supportive 
therapy is invasive and non- invasive mechanical 
ventilation.4 A considerable proportion of patients 
within ICU are mechanically ventilated, with audit 
data from the USA suggesting up to 40% of patients 
may be receiving mechanical ventilation at any 
given time. In the UK, an estimated 116 000 adult 
ICU admissions alone are for respiratory support 
per annum.5
Patients mechanically ventilated in the ICU for 
ARF can experience mucus accumulation due 
to several reasons including infection, muscle 
weakness, mucociliary escalator dysfunction and 
suppression of cough reflex due to analgesia and 
sedation used to facilitate ventilation.6 Targeted 
respiratory physiotherapy treatments, including 
mucoactive agents, are used to manage secretion 
retention.7 8 Mucoactive agents are a class of medi-
cations that aid the removal of mucus from the 
lung and are generally subclassified according to 
their mechanism of action.9 Mucolytics, such as 
N- acetylcysteine (NAC), work by breaking mucin 
crosslinking, mucoregulators such as carbocisteine 
decrease mucus production, expectorants such as 
hypertonic saline (HTS) work by increasing water 
content, and mucokinetics such as ambroxol work 
by increasing pulmonary mucus transport by acting 
on the cilia. This classification is not strict as it is 
known that some mucoactive agents, such as HTS, 
have multiple mechanisms of action.10 They can be 
delivered to patients either via inhalation direct to 
the lungs or systemically; oral or intravenous.
There are no systematic reviews on the use of 
mucoactive agents in mechanically ventilated or high- 
flow nasal oxygen (HFNO) populations specific to 
ARF. Furthermore, the National Institute for Health 
and Care Excellence,11 the British Thoracic Society12 
Key messages
What is the key question?
 ► Do mucoactive agents improve clinically 
important outcomes in critically ill, ventilated 
patients with acute respiratory failure?
What is the bottom line?
 ► This systematic review found limited trials and 
evidence that mucoactives improved clinically 
important outcomes in patients ventilated with 
acute respiratory failure.
Why read on?
 ► We describe four mucoactive agents across 13 
trials and explain why we urge mucoactive use 
with caution in this population.
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Figure 1 PRISMA flow diagram. PRISMA, Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses.
Figure 2 Risk of bias for included trials. (van Meenen 2018 had stated 
in their protocol that an economic analysis would be performed. This 
however was not within the trial publication. Following correspondence 
with authors this was a shared decision by them and the editor of 
JAMA. This cost related data is currently being used to prepare a 
separate publication to be submitted aside of the main clinical results. 
therefore, we assessed rob for selective outcome reporting as low.) HTS, 
hypertonic saline; NAC, N- acetylcysteine.
and the Intensive Care Society12 13 do not provide published 
recommendations regarding mucoactive agent use in this popula-
tion. In contrast to the lack of evidence of efficacy, surveys show 
mucoactive agent usage is common14–16 with a recent survey of 
ICU- level practice finding mucoactive agents were used in 83% of 
ICU in the UK, although with notable variation in prescribing prac-
tices.17 This survey indicated high use of NAC, HTS and carbo-
cisteine, with the most highly ranked indication for use being thick 
secretions, and the most widely expected benefit that of reduced 
duration of mechanical ventilation. Practice relating to the use of 
mucoactive agents is currently guided by anecdotal evidence, local 
experience and clinician preference.
Objective
To systematically review the current evidence for the use of muco-
active agents in critically ill patients with ARF, with the objective of 
determining improvement on clinically important outcomes.
METhOds
Deviations between this review and protocol are listed in the 
online supplementary material.
Types of studies
We included any design of clinical trial that compared at least 
one mucoactive agent with standard care or placebo in venti-
lated patients (including HFNO) with ARF. We excluded obser-
vational, case series, pilot/feasibility and longitudinal studies.
Types of participants
We included trials that studied adults (at least 15 years old) who 
were mechanically ventilated, either invasively, non- invasively 
or had received HFNO for treatment of ARF. Invasive mechan-
ical ventilation was defined as a participant requiring an artificial 
tracheal airway. Non- invasive ventilation was defined as appli-
cation of respiratory support via a sealed face- mask, nasal mask, 
mouthpiece, or full face visor or helmet, without the need for 
tracheal intubation. HFNO was defined as any cannula sitting 
within the nostrils and delivering heated and humidified oxygen 
with a gas flow rate of ≥20 L/min.18 ARF was defined to include 
the following conditions: acute hypoxic respiratory failure (type 
1), acute hypercapnic respiratory failure (type 2), acute respiratory 
distress syndrome (ARDS) and acute lung injury (ALI). Patients 
could present with one or more of these conditions. Patients with 
pre- existing chronic respiratory conditions with sputum abnor-
malities such as bronchiectasis or cystic fibrosis were excluded, 
however, patients with other chronic respiratory conditions 
including chronic obstructive pulmonary disease (COPD) were 
included.
Types of interventions
We included trials involving at least one mucoactive agent. A 
mucoactive agent was defined as any agent used to assist the 
removal of mucus/sputum from the lungs.9 19 We included any 
method of delivery as mucoactive mechanisms of action impact 
on the same clinical outcomes.20 We did not regard isotonic 
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Table 1 Characteristics of included studies
Author and 
year
no of 
participants
Age (years, 
mean±sd)
Population
(ventilation as described in paper)
Mucoactive agent 
intervention and dose Control
duration to last 
follow- up (days)
Outcomes measured 
relevant for this r eview
Bandeshe38 
2016*
214 Placebo: 59
Usual care: 62
Intervention: 57
(reported as 
medians)
Mixed
(invasive mechanical ventilation)
Heparin
(Nebulised; 2 mL 5000 units 
every 6 hours)
Placebo (0.9%) NaCl
Usual care
Not reported Mortality, ICU stay, hospital 
stay, duration of mechanical 
ventilation and adverse 
events.
Bernard33 1997 46 Control: 47±4
Intervention: 43±6
ARDS
(mechanically ventilated)
NAC
(Intravenous; 70 mg/kg, 
every 8 hours, for 10 days)
Placebo
(5% dextrose in water)
30 Mortality, ventilator free days 
at day 30 and adverse events.
Dixon40 2010 50 Control: 55.5±17.0
Intervention: 
56.0±16.5
Mixed
(invasive mechanical ventilation)
Heparin
(Nebulised; 25 000 U/5 mL 
every 4 or 6 hours)
Placebo
(0.9% NaCl)
60 Mortality, ventilator free days 
at day 28, ICU stay, hospital 
stay and adverse events.
Domenighetti31 
1997
42 Control: 52.4±17
Intervention: 
52.1±17.8
ARDS
(invasive and non- invasive ventilation)
N- acetylcysteine
(Intravenous; 190 mg/kg/
day, for 2 days)
Placebo
(not defined in paper)
ICU discharge
(not reported)
Mortality, ICU stay, duration 
of ventilation and adverse 
events.
Jepsen35 1992 66 Control: 51.5
Intervention: 50.5
ARDS
(tracheal intubation)
N- acetylcysteine
(Intravenous; 150 mg/kg 
then 20 mg/kg/hour for 
6 days)
Placebo
(not defined in paper)
60 Mortality.
Masoompour30 
2015
40 Control: 50.6±21
Intervention: 
59.7±22
Mixed
(invasive ventilation)
N- acetylcysteine
(Nebulised; 2 mL of 20%, 3 
times per day)
Control
(isotonic saline)
1 Mortality.
Moradi37 2009 27 Control: 49.2±4.5
Intervention: 
48.4±5.5
ARDS/ALI
(mechanically ventilated)
N- acetylcysteine
Intravenous; 150 mg/kg 
diluted in 5% dextrose day 
1 then 50 mg/kg/day for 3 
consecutive days)
Placebo
(5% dextrose)
Not reported Mortality, ICU stay and 
duration of mechanical 
ventilation.
Ortolani36 2000 36 Control: 55±13
Intervention: 57±14
ARDS
(artificial ventilation)
N- acetylcysteine
(Intravenous; 50 mg/kg in 
5% dextrose, every 8 hours 
for 9 days)
Placebo
(5% dextrose in water)
30 Mortality and ICU stay.
Saleh39 2017 80 Control: 34.8±14.8
Intervention: 
34.3±14.6
ARDS
(mechanical ventilation)
Heparin
(Nebulised; 5000 IU heparin 
mixed with 3 mL of normal
Saline every 4 hours)
Standard Care
(Conventional 
management of 
ARDS: Mechanical 
ventilation with 
open lung protective 
strategy, conservative 
fluid management, 
solumedrol at a dose 
of 1 mg/kg/day, 
antimicrobials and 
bronchodilators if 
needed)
End of ICU stay Mortality, ICU stay and 
duration of mechanical 
ventilation.
Suter32 1994 61 Control: 48.1±21.9
Intervention: 
46.6±19.7
ALI
(invasive ventilation)
N- acetylcysteine
(Intravenous; 40 mg/kg/day 
for 3 days)
Placebo
(not defined in paper)
ICU discharge
(not reported)
Mortality, ICU stay and 
adverse effects.
Van Meenen26
(NEBULAE) 
2018†
922   Control: 66
  Intervention: 65
  (median values 
reported)
Mixed
(invasive)
On demand N- 
acetylcysteine
(Nebulised; 300 mg with 
2.5 mg salbutamol)
Routine N- 
acetylcysteine
(300 mg with 2.5 mg 
salbutamol, 4 times 
daily for upto 28 days)
90 Mortality, duration of 
ventilation, ventilator free 
days at day 28, ICU stay, 
hospital length of stay and 
adverse events.
Yong- Jun34 2014 68 Control: 57±8
Intervention: 58±12
ARDS
(invasive and non- invasive ventilation)
Ambroxol
(Intravenous; 1005 mg/day, 
for 7 days)
Placebo
(0.9% isotonic saline)
Not reported Duration of ventilation, ICU 
stay and hospital stay.
Dahruog 201729 60 Control: 
41.87±16.44
intervention: 
41.30±14.13
ARDS
(invasive ventilation)
Hypertonic saline
(nebulised; 3%, 4 mL once 
daily, for 7 days)
Control
(not defined in paper)
30 Mortality, duration of 
mechanical ventilation, ICU 
stay and adverse events.
*Standard care and placebo were combined as one group using methodology from the Cochrane Handbook Table 7.7, as this was a three arm trial comparing placebo, mucoactive and standard care.
†The control group (routine nebulisation) was regarded as mucoactive group in the analyses and the on- demand group was regarded as the control/standard care. The analyses compared the routine nebulisation group 
to a subset of patients from the on- demand group that received no nebulisations (n=268). This excluded patients that received NAC and salbutamol treatment in the control group.
ALI, acute lung injury; ARDS, acute respiratory distress syndrome; ICU, intensive care unit; NAC, N- acetylcysteine.
saline as an active mucoactive agent as it was used as the placebo/
control group in several trials.
Outcomes
The primary outcome for invasive/non- invasive ventilated 
patients was duration of ventilation and for HFNO patients was 
intubation rate. Secondary outcomes were time to extubation, 
reintubation, number of ventilator free days at day 28, dura-
tion of ICU stay, duration of hospital stay, mortality (all cause 
within 28, 60 and 90 days), health- related quality of life, adverse 
events/development of other pathologies and healthcare related 
costs. All outcomes included were from a recently published core 
outcome set for trials of interventions intending to modify the 
duration of mechanical ventilation.21
search strategy
We searched three electronic databases (MEDLINE, EMBASE, 
Cochrane Central Register of Controlled Trials), three clinical 
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Figure 3 Duration of ventilation. Forest plot of comparison: mucoactive agent versus placebo/standard care. HTS, hypertonic saline; IV, intravenous; 
NAC, N- acetylcysteine; Neb, nebuliser.
trial registries (EU Clinical Trial Register,  ClinicalTrials. gov, 
WHO trial registry) and grey literature (OpenGrey). With the 
aid of a medical librarian, a comprehensive search strategy was 
developed using appropriate Medical Subject Headings (MeSH) 
and keywords (online supplementary material). The references 
of relevant articles were also checked for potentially eligible 
trials. All searches were from database inception to 9 January 
2020. The search was for English language only articles.
data collection and analysis
Search results were imported into a systematic review manager 
(Covidence: www. covidence. org) for screening and data 
extraction.
selection of studies
Two review authors (RA and CY) independently screened titles 
and abstracts from the searches for inclusion. The full text of 
publications was retrieved for potentially eligible studies. Full- 
text publications were additionally also independently screened 
for inclusion by a third review author (DM) to confirm inclu-
sion. Any disagreements or uncertainties were resolved through 
discussion or with consultation of the other review authors.
data extraction
Data from included trials were extracted independently by two 
review authors (RA and CY) including: the type and setting 
of the study, number of participants, eligibility criteria (online 
supplementary material), nature of the intervention(s) in each 
group (dose and route of administration of mucoactive agent), 
time points of outcome measurement and results of outcomes. 
Any disagreements were resolved through discussion or with 
consultation of the other review authors. Study authors were 
contacted to request data that were not reported or insufficient 
in the main publication.
Assessment of risk of bias
Two review authors (RA and CY) independently used the Cochrane 
Risk of Bias tool for randomised trials within Covidence.22 Risk 
of bias was assessed across eight domains: sequence generation, 
allocation concealment, blinding of outcome assessors, blinding 
of participants, blinding of personnel, selective outcome 
reporting, incomplete outcome data and other sources of bias. 
Each potential source of bias was marked as high, low or unclear.
Measures of effect
The unit of analysis was the participant. Binary variables were 
calculated as odds ratios (ORs) with 95% confidence intervals 
(CIs). Continuous variables were calculated as mean differ-
ences (MDs) with 95% CIs. When analysing for mortality, we 
used the longest fully reported follow- up.23 Meta- analyses were 
performed using Review Manager V.5.3 and statistical hetero-
geneity evaluated using the I2 statistic, with a value of >50% 
implying substantial heterogeneity.24 Trials with standard care 
or a placebo as a comparator were grouped as ‘non- mucoactive 
agent’ and synthesised together. This was then compared with 
the pooled mucoactive group. We estimated mean values from 
trials that reported any relevant median values using methodol-
ogies from Wan et al.25 Analysis was undertaken using random 
methods models.
For the NEBULAE trial (Effect of On- Demand vs Routine 
Nebulization of Acetylcysteine With Salbutamol on Ventilator- 
Free Days in Intensive Care Unit Patients Receiving Invasive 
Ventilation),26 the control group (routine nebulisation of a muco-
active agent) was regarded as the mucoactive agent group in the 
analyses and the ‘on- demand’ group was regarded as the control/
standard care. The analyses compared the routine nebulisation 
group, that is, the intervention group to a subset of patients from 
the on- demand group that received no nebulisations, that is, the 
control group (n=268). This excluded patients that received 
NAC and salbutamol treatment in the control group. In the orig-
inal trial, the control group was the routine nebulisation group, 
and the intervention group was the on- demand group.
subgroup analysis
Where possible we performed meta- analysis based on specific 
mucoactive agent when there was adequate data. This included 
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Figure 4 Mortality. Forest plot of comparison: mucoactive agent versus placebo/standard care. HTS, hypertonic saline; IV, intravenous; M- H, Mantel- 
Haenszel; NAC, N- acetylcysteine; Neb, nebuliser.
a subgroup analysis of mucoactive agent type for duration of 
ventilation, mortality and duration of ICU stay. There were 
insufficient trials to test subgroup differences in other outcomes.
Sensitivity analysis
Sensitivity analyses were not undertaken due to the small number 
of trials and a lack of aggregate data.27
Quality of evidence
Five authors (RA, JB, BB, BC and BO) determined an overall 
certainty of the evidence for the outcomes using the principles 
of the GRADE system (Grades of Recommendation, Assessment, 
Development and Evaluation) to rate the strength of findings into 
one of four levels: high, moderate, low or very low.28 We gener-
ated a ‘Summary of Findings’ table using GRADEpro software 
( www. gradepro. org) to present outcome- specific information 
regarding overall certainty of evidence from studies. Certainty 
of evidence was assessed according to study design, risk of bias, 
inconsistency, indirectness, imprecision, publication bias and any 
other factors, for example, confounding and downgraded by one 
(for serious) or two (for very serious) levels as necessary.
rEsulTs
literature search
The search identified 557 results (figure 1). After importing into 
covidence, five duplicates were identified and removed. After 
title and abstract screening, 510 records were excluded leaving 
42 records for full text screening. After full- text screening, 13 
completed trials were eligible for inclusion in the review26 29–40 
with two trials identified as ongoing.41 42 A list of the 27 excluded 
studies, with reasons for exclusion, are within the online 
supplementary material. Also included within the online supple-
mentary material are the numbers of search results found from 
each data resource.
study characteristics and risk of bias
Characteristics of included trials are summarised in table 1. All 
studies were prospective randomised parallel group controlled 
trials, totalling 1712 patients. Mucoactive agents investigated 
included NAC (n=8 trials), heparin (n=3 trials), ambroxol 
(n=1 trial) and HTS (n=1). Nine trials included patients with 
ALI or ARDS, and four trials with a mixed ARF population. The 
number of participants in the trials ranged from 27 to 922. The 
longest follow- up was reported at 90 days. No trials involved 
patients receiving HFNO.
Risk of bias assessment is described in figure 2. Six 
trials26 29 30 33 36 40 were judged as high risk of bias in at least 
one domain, six trials31 32 34 35 37 39 were deemed as an unclear 
risk of bias across at least three domains and one trial36 overall 
had a low risk of bias. Ten trials29–37 39 had high or unclear risk 
of bias due to allocation concealment and nine29–32 34–37 39 due 
to sequence generation. Twelve26 29–37 39 40 trials had high or an 
unclear risk of bias due to blinding. All trials were at a low risk 
of attrition bias. One trial33 was at high risk of reporting bias.
duration of mechanical ventilation
The duration of mechanical ventilation was reported in seven 
trials26 29 31 34 37–39 (n=1226 patients). Pooled analysis showed 
no effect with the use of mucoactive agents with high hetero-
geneity (MD −1.34, 95% CI −2.97 o 0.29, p=0.11, I2=82%) 
(figure 3). There was no noticeable publication bias with funnel 
plot estimates (online supplementary material).
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Figure 5 Duration of ICU stay. Forest plot of comparison: mucoactive agent versus placebo/standard care. HTS, hypertonic saline; ICU, intensive care 
unit; IV, intravenous; NAC, N- acetylcysteine; Neb, nebuliser.
Figure 6 Duration of hospital stay. Forest plot of comparison: mucoactive agent versus placebo/standard care. IV, intravenous; NAC, N- 
acetylcysteine; Neb, nebuliser.
Mortality
Mortality was reported in 12 trials26 29–33 35–40 (n=1428 patients). 
Mucoactive agents had no effect on mortality (OR 0.75, 95% CI 
0.52 to 1.08, p=0.12, I2=32%). Subgroup analysis showed no 
difference in reduction of mortality with use of NAC intravenous 
(OR 0.72, 95% CI 0.42 to 1.24, p=0.24, I2=3%), NAC neb 
(OR 0.98, 95% CI 0.55 to 1.74, p=0.94, I2=26%) or heparin 
(OR 0.89, 95% CI 0.50 to 1.58, p=0.69, I2=0%) all with low 
heterogeneity (figure 4). There was no noticeable publication 
bias with funnel plot estimates (online supplementary material).
duration of ICu stay
Duration of ICU stay was reported in 10 trials26 29 31 32 34 36–40 
(n=1362 patients). There was a difference in duration of ICU 
stay favouring the use of mucoactive agents with high hetero-
geneity (overall MD −3.22, 95% CI −5.49 to 0.96, p=0.005, 
I2=89%). Subgroup analysis showed a difference in reduction of 
ICU stay with NAC intravenous with low heterogeneity (overall 
MD −4.70, 95% CI −7.92 to −1.48, p=0.004, I2=25%) and 
no difference in ICU stay with the use of nebulised heparin 
(overall MD −3.01, 95% CI −6.91 to 0.88, p=0.13, I2=85%) 
(figure 5). There was slight publication bias with funnel plot esti-
mates (online supplementary material).
duration of hospital stay
The duration of hospital stay was reported in four trials26 34 38 40 
(1067=patients). Pooled analysis showed no difference with the 
use of mucoactive agents with high heterogeneity (overall MD 
−2.05, 95% CI −5.87 to 1.76, p=0.29, I2=81%) (figure 6).
Ventilator free days
Three trials reported ventilator- free days, two at day 2826 40 
and one trial reported at day 30.33 Pooled analysis showed no 
difference in the number of ventilator free days at day 28 
with high heterogeneity (overall MD 2.35, 95% CI −1.76 to 
6.45, p=0.26, I2=77%) (figure 7). For one study,33 the median 
number of ventilator free days was 11 for the mucoactive agent 
group and three for the placebo group. This study could not be 
incorporated into the meta- analysis as the mean (SD) could not 
be estimated.
Intubation rate, time to extubation, reintubation, health-
related quality of life and healthcare-related costs
No trials reported outcomes for intubation rate, time to extu-
bation, reintubation, health- related quality of life or healthcare- 
related costs.
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Table 2 GADE and summary of findings
summary of findings: mucoactive agents compared with non- mucoactive agents for acute respiratory failure
Patient or population: ventilated with acute respiratory failure
setting: intensive care unit (ICu)
Intervention: mucoactive agents
Comparison: non- mucoactive agents
Outcomes
№ of participants
(studies)
Follow- up
Certainty of the 
evidence
(GrAdE)
relative effect
(95% CI)
Anticipated absolute effects
risk with non- mucoactives risk difference with mucoactives
Duration of ventilation 1226
(7 RCTs)
⨁◯◯◯
VERY LOW*
– The mean duration of Ventilation was 0 MD 1.34 lower
(2.97 lower to 0.29 higher)
Mortality 1428
(12 RCTs)
⨁⨁⨁◯
MODERATE†
Or 0.75
(0.52 to 1.08)
336 per 1000 61 fewer per 1000
(128 fewer to 17 more)
Duration of ICU stay 1362
(10 RCTs)
⨁◯◯◯
VERY LOW‡
– The mean duration of ICU stay was 0 MD 3.22 lower
(5.49 lower to 0.96 lower)
Duration of hospital stay 1067
(4 RCTs)
⨁◯◯◯
VERY LOW§
– The mean duration of Hospital stay was 0 MD 2.05 lower
(5.87 lower to 1.76 higher)
Ventilator free days at day 28 785
(2 RCTs)
⨁◯◯◯
VERY LOW¶
– The mean ventilator- free days at day 28 was 0 MD 2.35 higher
(1.76 lower to 6.45 higher)
GRADE working group grades of evidence: High certainty: We are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: We are moderately confident in the effect estimate: 
The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially 
different from the estimate of the effect. Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect.
The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
*Risk of bias was deemed serious as the majority of trials (6/7) had an unclear or high risk of bias in at least one domain. Inconsistency was deemed as very serious due to high heterogeneity (I2=82%).
†Risk of bias was deemed serious as the majority of trials (11/12) had an unclear or high risk of bias in at least one domain.
‡Risk of bias was deemed serious as the majority of trials (9/10) had an unclear or high risk of bias in at least one domain. Inconsistency was deemed as very serious due to high heterogeneity (I2=89%).
§Risk of bias was deemed serious as the majority of trials (3/4) had an unclear or high risk of bias in at least one domain. Inconsistency was deemed as very serious due to high heterogeneity (I2=81%).
¶Risk of bias was deemed serious as both trials (2/2) had an unclear or high risk of bias in at least one domain. Inconsistency was deemed as very serious due to high heterogeneity (I2=77%).
GRADE, Grades of Recommendation, Assessment, Development and Evaluation; MD,mean difference.
Figure 7 Ventilator free days at day 28. Forest plot of comparison: mucoactive agent versus placebo/standard care. IV, intravenous; NAC, N- 
acetylcysteine; Neb, nebuliser.
Adverse events and development of other pathologies
Three trials,26 33 38 investigating nebulised NAC, intravenous 
NAC and nebulised Heparin, respectively, reported on adverse 
events in both arms. Four further trials reported the number of 
adverse events only in the mucoactive agent arm of the study. 
Two trials analysed differences between groups. The NEBULAE 
trial26 reported that the proportion of patients developing one or 
more nebulisation- related adverse events was significantly higher 
in the mucoactive group that received nebulised NAC (p<0.001), 
however, the development of other pathologies/pulmonary compli-
cations were not significantly different between the two groups. 
One trial,29 investigating nebulised HTS, reported a significantly 
higher development of ventilator associated pneumonia in the 
control group, but did not report the original number of events in 
each arm (p=0.014). One trial40 investigating nebulised heparin 
reported no differences in number of days that patients had blood 
stained sputum. Further details on adverse events are summarised 
in the online supplementary material.
summary of findings
Certainty of evidence is summarised in table 2. Downgrading 
of certainty levels was primarily related to high risk of bias and 
imprecision (high heterogeneity).
dIsCussIOn
This systematic review found that use of mucoactive agents 
did not improve outcomes including duration of ventilation, 
mortality, duration of hospital stay or ventilator- free days at day 
28, although they did decrease ICU stay. The GRADE evaluation 
showed that the certainty level of evidence for four outcomes in 
the review was very low, with only mortality having a moderate 
level of certainty of evidence. Certainty of the evidence was 
primarily impacted by a risk of bias mostly related to random 
sequence generation and allocation concealment. We note there 
are differences in our risk of bias assessment in some trials that 
were also included in a previous review, these are explained 
in the online supplementary material. Other reasons affecting 
the evidence included small sample size, mixed patient popula-
tions and high heterogeneity. Our findings indicate that further 
evidence is required to determine the effectiveness of mucoactive 
agents for critically ill patients with ARF. Future trials should be 
designed to address the methodological limitations identified in 
studies included in this review. Our systematic review echoes a 
previous expert narrative review in 2017 which concluded use of 
mucoactive agents within the critically ill is in need of evidence- 
based recommendations.19
Two mucoactive agents that are used within critical care units, 
recombinant human DNase (also known as RhDNase) and carbo-
cisteine were not investigated in trials in this review, therefore, 
highlighting the lack of evidence to support their use in venti-
lated patients with ARF. This mirrors findings from a review 
of aerosolised mucoactive agents in hospitalised patients43 and 
guidelines by The American Association for Respiratory Care,44 
although these publications were not targeted at critically 
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ill patients in the ICU. There is evidence of effect with these 
mucoactive agents in other respiratory conditions. Carbocisteine 
shows benefit for patients with COPD45 and RhDNase for cystic 
fibrosis.46 However, it should not be assumed that a mucoactive 
agent demonstrated to be effective in one clinical population 
will necessarily be effective in another population and indeed 
there may be potential for harm. For example, although there is 
evidence to support RhDNase in cystic fibrosis, a well- designed 
and powered clinical trial showed it was not effective and poten-
tially harmful in a bronchiectasis population.47 We note that 
there is an active trial exploring the use of nebulised RhDNase in 
ventilated ARF patients. This trial aims to recruit 500 patients to 
explore the use of to reduce the incidence of ARDS.48 Expected 
to complete in 2021, it will likely provide evidence to guide the 
use of RhDNase.
Eight trials in this review explored the effectiveness of intra-
venous NAC and a subgroup analysis highlighted that there was 
no benefit in mortality or duration of ventilation, however, there 
was a reduction in ICU stay. Our analysis of NEBULAE,26 with 
nebulised NAC, showed no improvement with outcomes with 
some evidence suggesting it may be associated with more adverse 
events. Our review supports the conclusions of a previous system-
atic review highlighting the need for more data to support use of 
NAC in the critically ill.49 Another review focusing on NAC use in 
ARDS also found a reduction of ICU stay based on three trials.50 
However, they did not use the full core outcome set21 for venti-
lated trials or search for HFNO trials. There is a small ongoing trial 
expected to be complete later this year, exploring nebulised NAC 
in 52 ARDS patients.51
The second most common mucoactive explored in this review 
was nebulised heparin, showing no improvement in clinical 
outcomes with the exception of one trial40 showing an improve-
ment in ventilator free days. One trial that explored ambroxol 
showed improvements in duration of ventilation and reduced ICU 
and hospital stay. However, we acknowledge that ambroxol is 
not available in the UK. One trial29 exploring the efficacy of HTS 
showed significant reductions in mortality, duration of mechanical 
ventilation and ICU stay but this trial was small and methodolog-
ically flawed.
Our recent survey of ICU unit level practice17 and a point prev-
alence survey52 exploring the use of mucoactive agents in ARF, 
showed HTS and carbocisteine are the most commonly used. 
Alongside this review, it provides justification for a clinical trial to 
explore the effectiveness of these mucoactive agents in ARF. These 
interventions could have adverse effects, and the resource use in 
terms of staff time to administer therapy, particularly those that are 
nebulised, may be significant. Conversely if any of these mucoact-
ives have a positive significant impact on clinical outcomes there 
is also potential for savings such as reduced costs associated with 
shortened critical care and hospital stay. Also, these therapies are 
individually inexpensive, and a lack of robust evidence to support 
their use in practice may not deter some clinicians from continuing 
to prescribe them regardless of effectiveness. Nonetheless, as they 
are used in large numbers of critically ill patients, the overall scaled 
cost might be substantial.
The strength of our review is that it followed prespecified 
methods using a published protocol (PROSPERO) with duplicate 
and independent screening and data extraction. We also obtained 
a subgroup of data from one large trial to strengthen the meta- 
analysis providing a more accurate estimate of effect and used 
a full core outcome set21 with a five member panel grading the 
quality of evidence for each outcome. The major limitations of the 
results are the relatively small number and large heterogeneity of 
included trials, the low quality of evidence, and lack of relevant 
reported outcomes and associated data. Not all trials reported fully 
on adverse events which leaves important questions surrounding 
the safety and tolerability of mucoactive agents.
Conclusion
In conclusion, the evidence in this review suggests that use of 
mucoactive agents does not improve most clinical outcomes 
in ventilated patients with ARF. The findings do not support 
the current widespread clinical practice of various mucoactive 
agents in mechanically ventilated patients with ARF. However, 
there was considerable heterogeneity in included trials and 
the certainty of this evidence is low. Therefore, until further 
evidence is available, mucoactive agent use should be consid-
ered with caution in this population. This systematic review 
justifies investment in large, high- quality randomised controlled 
trials to explore the use of commonly used mucoactive agents, 
where evidence does not already exist (eg, carbocisteine) or is 
not adequate (eg, HTS), to inform practice. Such trials should 
include appropriate outcomes from the core outcome set for 
ventilated trials21 and report fully on adverse events.
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